Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Operating Expenses data on record, last reported at $36.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 8.46% year-over-year to $36.6 million; the TTM value through Dec 2025 reached $153.3 million, down 61.88%, while the annual FY2025 figure was $153.3 million, 61.88% down from the prior year.
  • Operating Expenses reached $36.6 million in Q4 2025 per AMLX's latest filing, up from $36.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $210.8 million in Q1 2024 and bottomed at $12.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $60.2 million, with a median of $51.0 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: skyrocketed 271.57% in 2022, then tumbled 82.06% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $28.3 million in 2021, then skyrocketed by 134.78% to $66.5 million in 2022, then skyrocketed by 60.23% to $106.5 million in 2023, then tumbled by 62.46% to $40.0 million in 2024, then decreased by 8.46% to $36.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $36.6 million in Q4 2025, $36.0 million in Q3 2025, and $42.9 million in Q2 2025.